Skip to content

Released Nov 5, 2020, after the close

10-Q filed Nov 5, 2020, 36 days after period end · 0001564590-20-051470

Q3 2020 · 10-Q
Revenue$34.61M+718.0% vs Q3 2019−12.1% vs Q2 2020
Net Income-$3.35MN/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.09N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$4,019,000N/M
Operating Cash Flowderived$10,646,000N/M
Free Cash Flowderived$10,646,000N/M
Margins · derived
Operating margin-11.6%+602.7 pt vs Q3 2019
Net margin-9.7%+581.1 pt vs Q3 2019

What the release said

The release

Same quarter

MetricQ3 2020Q3 2019Q3 2018Q3 2017
Revenue$34.61M$4.23M$4.29M$2.66M
Net Income-$3.35M-$25.00M-$21.54M-$12.27M
EPS Diluted-$0.09-$0.96-$0.87-$710.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR